已收盘 07-02 16:00:00 美东时间
+4.230
+1.10%
今日重点评级关注:Chardan Capital:维持EyePoint"买入"评级,目标价从29美元升至65美元;康托·菲茨杰拉德:维持Hyperliquid Strategies"超配"评级,目标价从8美元升至18.4美元
07-02 18:41
Benchmark analyst Mark Palmer maintains Dave (NASDAQ:DAVE) with a Buy and raises the price target from $345 to $475.
07-01 23:31
今日重点评级关注:Piper Sandler:维持Tenax Therapeutics"超配"评级,目标价从20美元升至50美元;Tigress Financial:维持优步"买入"评级,目标价从110美元升至115美元
06-15 08:32
Barrington Research analyst Gary Prestopino maintains Dave (NASDAQ:DAVE) with a Outperform and raises the price target from $290 to $310.
06-12 23:20
Shares of companies within the broader financials sector are trading lower, pos...
06-04 03:49
今日重点评级关注:Tigress Financial:维持英伟达"强力买入"评级,目标价从360美元升至425美元;康托·菲茨杰拉德:维持DeFi Development"超配"评级,目标价从6美元升至7美元
05-28 19:00
今日重点评级关注:Canaccord Genuity:维持Dakota Gold"投机性买入"评级,目标价从16美元升至18美元;瑞杰金融:上调Tectonic Therapeutic评级至"强烈买入",目标价从76美元升至81美元
05-27 17:33
Shares of banks and financial services companies are trading higher as optimism...
05-27 02:09
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
今日重点评级关注:Citizens:维持Avalo Therapeutics"跑赢大市"评级,目标价从52美元升至62美元;BTIG:维持Avalo Therapeutics"买入"评级,目标价从40美元升至58美元
05-07 12:37